1)Cushing MM, DeSimone RA, Goel R, et al : The impact of Daratumumab on transfusion service costs. Transfusion 59:1252-1258,2019
2)Nooka AK, Kaufman JL, Hofmeister CC, et al : Daratumumab in multiple myeloma. Cancer 125:2364-2382,2019
3)Quach H, Benson S, Haysom H, et al : Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J 48:210-220,2018
4)日本輸血・細胞治療学会 輸血検査技術講習委員会:多発性骨髄腫治療薬(抗CD38)による偽陽性反応への対処法(一部改定版)(http://yuketsu.jstmct.or.jp/wp-content/uploads/2017/11/158dcb8f65fabdf76c2cdde9d008daee.pdf)(2019年10月30日アクセス)
5)日本臨床衛生検査技師会(監):輸血・移植検査技術教本.丸善出版,2016
6)Fung MK, Eder AF, Spitalnik SL, et al (eds) : Technical Manual, 19th ed. AABB, Bethesda, MD,2017
7)Yeh TJ, Yeh CJ, Liu YC, et al : Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Transfusion 59:2751-2752,2019
8)Chinoca Ziza KN, Paiva TA, Mota SR, et al : A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing. Transfusion 59:1827-1835,2019
9)de Vooght KMK, Lozano M, Bueno JL, et al : Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy : summary. Vox Sang 113:492-498,2018